Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

Open in Screener

ILMN

Illumina Inc

Nov 25 • 04:00PM ET

129.64

+3.68 2.92 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: PACB VRTX TXG QGEN GH BIO MYGN IONS TWST OMIC

| Held by: IJH VTI VB VBR VXF MDY IBB ARKK SPMD COWZ

Index	-	P/E	29.04	EPS (ttm)	4.46	Insider Own	2.81%	Shs Outstand	153.00M	Perf Week	6.29%
Market Cap	19.81B	Forward P/E	25.93	EPS next Y	5.00	Insider Trans	0.01%	Shs Float	148.51M	Perf Month	29.19%
Enterprise Value	21.11B	PEG	2.62	EPS next Q	1.22	Inst Own	104.14%	Short Float	4.53%	Perf Quarter	30.24%
Income	703.00M	P/S	4.62	EPS this Y	13.26%	Inst Trans	0.68%	Short Ratio	3.88	Perf Half Y	53.55%
Sales	4.29B	P/B	8.33	EPS next Y	6.10%	ROA	11.53%	Short Interest	6.73M	Perf YTD	-2.99%
Book/sh	15.56	P/C	15.50	EPS next 5Y	11.07%	ROE	31.20%	52W High	153.06 -15.30%	Perf Year	-5.37%
Cash/sh	8.36	P/FCF	19.81	EPS past 3/5Y	- -	ROIC	18.11%	52W Low	68.70 88.70%	Perf 3Y	-39.52%
Dividend Est.	-	EV/EBITDA	18.95	Sales past 3/5Y	-1.15% 4.29%	Gross Margin	66.79%	Volatility	4.58% 4.69%	Perf 5Y	-54.82%
Dividend TTM	-	EV/Sales	4.93	EPS Y/Y TTM	144.91%	Oper. Margin	19.58%	ATR (14)	5.10	Perf 10Y	-23.11%
Dividend Ex-Date	-	Quick Ratio	1.12	Sales Y/Y TTM	-2.39%	Profit Margin	16.41%	RSI (14)	70.78	Recom	2.48
Dividend Gr. 3/5Y	- -	Current Ratio	1.43	EPS Q/Q	-77.89%	SMA20	8.59%	Beta	1.44	Target Price	118.89
Payout	-	Debt/Eq	1.08	Sales Q/Q	0.28%	SMA50	21.98%	Rel Volume	0.92	Prev Close	125.96
Employees	10370	LT Debt/Eq	0.63	Earnings	Oct 30 AMC	SMA200	38.19%	Avg Volume	1.73M	Price	129.64
IPO	Jul 28, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	14.68% 1.74%	Trades		Volume	1,586,889	Change	2.92%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-12-25	Downgrade	Daiwa Securities	Outperform → Neutral	$94
Jul-11-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform	$125
Mar-04-25	Reiterated	Citigroup	Neutral	$130 → $90
Feb-28-25	Downgrade	HSBC Securities	Buy → Hold	$100
Feb-10-25	Downgrade	Barclays	Equal Weight → Underweight	$130 → $100
Feb-07-25	Downgrade	TD Cowen	Buy → Hold	$177 → $140
Dec-11-24	Downgrade	Citigroup	Buy → Neutral	$190 → $165
Nov-12-24	Resumed	Morgan Stanley	Equal-Weight	$156
Oct-17-24	Upgrade	HSBC Securities	Hold → Buy	$180
Aug-28-24	Upgrade	Argus	Hold → Buy
Aug-16-24	Upgrade	Daiwa Securities	Neutral → Buy	$120 → $154
Aug-14-24	Upgrade	TD Cowen	Hold → Buy	$126 → $144
Aug-14-24	Upgrade	Barclays	Underweight → Equal Weight	$125
Jul-10-24	Upgrade	Citigroup	Neutral → Buy	$140
Jun-03-24	Resumed	Jefferies	Hold	$115
Jan-16-24	Downgrade	HSBC Securities	Buy → Hold
Jan-04-24	Downgrade	TD Cowen	Outperform → Market Perform	$144
Dec-18-23	Upgrade	Scotiabank	Sector Perform → Sector Outperform	$185
Dec-15-23	Upgrade	Bernstein	Underperform → Mkt Perform
Dec-14-23	Initiated	Stephens	Overweight	$170

Show Previous Ratings

Nov-20-25 04:15PM	Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth (Business Wire)
05:00AM	Roche inks deal for rights to Freenome cancer tests outside US (MedTech Dive)
Nov-19-25 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Nov-18-25 11:01PM	3 Reasons to Sell ILMN and 1 Stock to Buy Instead (StockStory)
08:48AM	Top 3 Genomics Stocks to Consider for Your Portfolio (Zacks)
12:00PM	Loading…
Nov-12-25 12:00PM	Illumina whole-genome sequencing provides greater insight into genetic signals behind common diseases--according to Nature study (PR Newswire)
Nov-11-25 04:05PM	Illumina To Webcast Upcoming Investor Conference (PR Newswire)
11:40AM	ALKS or ILMN: Which Is the Better Value Stock Right Now? (Zacks)
Nov-10-25 01:31PM	Final Trades: Morgan Stanley, Cisco Systems, Illumina and FTAI Aviation (CNBC TV)
12:15PM	Illumina Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks (PR Newswire)
Nov-06-25 05:33AM	Illumina says China is lifting export ban (MedTech Dive)
12:37AM	5 Revealing Analyst Questions From Illumina's Q3 Earnings Call (StockStory)
Nov-05-25 05:16PM	Illumina Responds to Positive Updates from Chinese Ministry of Commerce (PR Newswire)
04:55AM	China Ends Levies on US Farm Goods, Halts Export Curbs on Firms (Bloomberg)
Nov-03-25 01:16PM	Illumina (ILMN) Stock Trades Down, Here Is Why (StockStory)
01:34AM	Loading…
01:34AM	Illumina (ILMN) Soars 23.4% on Earnings Beat (Insider Monkey)
Nov-01-25 02:48PM	Illumina (ILMN) Jumps 24.8% on Earnings Beat (Insider Monkey)
Oct-31-25 07:47PM	Analyst Report: Illumina, Inc. (Morningstar Research) +24.78%
07:35PM	Closing Bell Movers: Amazon soars to all-time highs on earnings (TipRanks)
02:07PM	'Hopeful' We'll Find Long-term Solution On China: Illumina CEO (Bloomberg)
01:01PM	Why Illumina (ILMN) Stock Is Up Today (StockStory)
08:47AM	ILMN Q3 Deep Dive: Clinical Sequencing Momentum and Cost Discipline Drive Outperformance (StockStory)
Oct-30-25 11:01PM	Illumina Inc (ILMN) Q3 2025 Earnings Call Highlights: Strong EPS Growth and Strategic ... (GuruFocus.com)
07:30PM	Compared to Estimates, Illumina (ILMN) Q3 Earnings: A Look at Key Metrics (Zacks)
05:35PM	Illumina (ILMN) Beats Q3 Earnings and Revenue Estimates (Zacks)
04:35PM	Illumina: Q3 Earnings Snapshot (Associated Press Finance)
04:23PM	Illumina (NASDAQ:ILMN) Beats Q3 Sales Expectations (StockStory)
04:05PM	Illumina Reports Financial Results for Third Quarter of Fiscal Year 2025 (PR Newswire)
Oct-28-25 11:14PM	What To Expect From Illumina's (ILMN) Q3 Earnings (StockStory)
Oct-27-25 10:00AM	Axsome Therapeutics (AXSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
10:00AM	Loading…
Oct-23-25 10:00AM	Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-21-25 09:43AM	Keros Therapeutics (KROS) Moves 9.8% Higher: Will This Strength Last? (Zacks)
Oct-20-25 05:14PM	Final Trades: Illumina, Columbia Banking, Alibaba and JPMorgan Chase (CNBC TV)
10:10AM	PacBio Aims to Expand Multiomic Capabilities Via Latest Innovations (Zacks)
Oct-19-25 08:01PM	To hit back at the United States in their trade war, China borrows from the US playbook (Associated Press Finance)
Oct-16-25 05:18PM	Roche Sets Gene-Sequencing Record. It's a Challenge for Illumina. (Barrons.com)
Oct-15-25 11:40AM	KMDA or ILMN: Which Is the Better Value Stock Right Now? (Zacks)
09:15AM	Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights (PR Newswire)
09:15AM	Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot (PR Newswire)
Oct-14-25 04:05PM	Illumina to Announce Third Quarter 2025 Financial Results on Thursday, October 30, 2025 (PR Newswire)
Oct-10-25 08:50AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
Oct-09-25 09:50AM	Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term (Zacks)
Oct-07-25 12:10PM	Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Oct-06-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Oct-03-25 08:44AM	ILMN Stock Set to Benefit From the Launch of New BioInsight Division (Zacks)
12:05AM	Genomics, Illumina team up to capture Asia-Pacific whole genome sequencing market (DigiTimes)
Oct-02-25 03:20PM	Why Illumina (ILMN) Shares Are Falling Today (StockStory)
09:15AM	Illumina to Join Pharma Partners for CDx Development on KRAS Biomarker (Zacks)
01:53AM	Illumina (ILMN) Expands TruSight Oncology Test With New KRAS CDx Collaborations (Insider Monkey)
Oct-01-25 04:00PM	Why Is Illumina (ILMN) Stock Rocketing Higher Today (StockStory) +7.68%
09:05AM	Illumina launches new business to accelerate technology and data-driven discovery (PR Newswire)
Sep-30-25 10:05AM	PacBio Enters Carrier Screening Market With PureTarget Expansion (Zacks)
Sep-29-25 11:40AM	KMDA vs. ILMN: Which Stock Is the Better Value Option? (Zacks)
Sep-26-25 09:21AM	TEM vs. ILMN: Which Precision Oncology Stock Is Worth Buying Now? (Zacks)
Sep-25-25 12:41AM	It isnt your imagination: Google Cloud is flooding the zone (TechCrunch)
Sep-23-25 09:50AM	Here's Why Illumina (ILMN) is a Strong Momentum Stock (Zacks)
09:15AM	Illumina advances personalized cancer care with new pharma development partnerships (PR Newswire)
08:32AM	Tempus AI Enhances Cancer Research Tools With FDA-Cleared xR IVD (Zacks)
Sep-22-25 09:16AM	Brown Advisory Global Leaders Strategy Exited Illumina (ILMN) in Q2. Here's Why (Insider Monkey)
Sep-18-25 11:35AM	3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025 (Zacks)
09:15AM	Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine (PR Newswire)
Sep-15-25 01:07PM	CDC vaccine panel to meet this week: Here's what's at stake (CNBC TV) +6.10%
Sep-12-25 04:00PM	Why Illumina (ILMN) Stock Is Falling Today (StockStory)
Sep-09-25 08:04AM	ILMN Stock to Gain From the Launch of Illumina Protein Prep Assay (Zacks)
Sep-08-25 12:02AM	Illumina (ILMN): Buy, Sell, or Hold Post Q2 Earnings? (StockStory)
Sep-03-25 11:30AM	CRISPR Therapeutics (CRSP) Down 5.3% Since Last Earnings Report: Can It Rebound? (Zacks)
09:15AM	Illumina Protein Prep launches to drive greater proteomic insights for improved drug discovery and development (PR Newswire)
Sep-01-25 09:50AM	Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term (Zacks)
Aug-31-25 11:35PM	Life Sciences Tools & Services Stocks Q2 Results: Benchmarking Illumina (NASDAQ:ILMN) (StockStory)
Aug-18-25 09:00AM	Press Release Biocartis NV: Biocartis Welcomes Mike Kreitzinger as Senior Vice President of Global Business Development (GlobeNewswire)
Aug-15-25 09:15AM	TMO Receives FDA Approval for Oncomine Dx Target Test (Zacks)
Aug-14-25 04:01PM	BioStem Technologies Appoints Brandon Poe as Chief Financial Officer (GlobeNewswire)
11:40AM	KMDA vs. ILMN: Which Stock Is the Better Value Option? (Zacks)
Aug-13-25 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
07:30AM	[Latest] Global AI in Synthetic Biology Market Size/Share Worth USD 192.95 Billion by 2034 at a 28.63% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) (GlobeNewswire)
12:22AM	Illumina's Q2 Earnings Call: Our Top 5 Analyst Questions (StockStory)
12:17AM	ILMN Q2 Deep Dive: Clinical Demand Cushions Revenue Decline Amid Research Weakness and Margin Pressures (StockStory)
Aug-12-25 10:30PM	[Latest] US Personalized Medicine Market Size/Share Worth USD 252.93 Billion by 2034 at a 17.32% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) (GlobeNewswire)
04:02PM	GRAIL Reports Second Quarter 2025 Financial Results (PR Newswire)
05:32AM	US Personalized Medicine Market Trends and Company Analysis Report 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La Roche (GlobeNewswire)
Aug-11-25 04:01PM	Standard BioTools Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-05-25 09:15AM	Illumina (ILMN) Reliance on International Sales: What Investors Need to Know (Zacks)
09:04AM	Does Illumina (ILMN) have an Attractive Risk-Reward Opportunity for Long-Term Investors? (Insider Monkey)
Aug-02-25 10:00AM	Illumina: Will big Pharma come to its rescue? Its CEO thinks so. (Yahoo Finance)
Aug-01-25 02:17PM	Top Technology Executives Recognized at the 2025 Minnesota ORBIE Awards (GlobeNewswire) -7.84%
12:20PM	Why Illumina (ILMN) Shares Are Falling Today (StockStory)
09:37AM	Analyst Report: Illumina, Inc. (Morningstar Research)
07:08AM	DOJ reaches $9.8 million settlement with Illumina over cyber whistleblower claims (Cybersecurity Dive)
Jul-31-25 07:00PM	Illumina: A 5.2 Rating Amid Challenges and Opportunities (Motley Fool)
06:30PM	Compared to Estimates, Illumina (ILMN) Q2 Earnings: A Look at Key Metrics (Zacks)
05:35PM	Illumina (ILMN) Q2 Earnings and Revenues Surpass Estimates (Zacks)
05:02PM	Illumina (NASDAQ:ILMN) Surprises With Q2 Sales (StockStory)
04:38PM	Illumina: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Illumina Reports Financial Results for Second Quarter of Fiscal Year 2025 (PR Newswire)
Jul-30-25 09:44AM	3 Genomics Stocks Worth Adding to Your Portfolio in 2025 (Zacks)
09:15AM	Gear Up for Illumina (ILMN) Q2 Earnings: Wall Street Estimates for Key Metrics (Zacks)
09:15AM	Illumina enhances flagship assay to accelerate access to comprehensive tumor profiling (PR Newswire)
Jul-29-25 11:07PM	Illumina (ILMN) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Jul-28-25 12:01PM	Illumina (ILMN) Stock Is Up, What You Need To Know (StockStory)
10:00AM	CRISPR Therapeutics AG (CRSP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release (Zacks)

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ILLUMINA, INC.	10% Owner	Nov 17 '25	Sale	79.85	1,000,000	79,850,000	3,502,126	Nov 18 09:33 PM
SCOTT DAVIES	Officer	Nov 12 '25	Proposed Sale	122.79	323	39,661		Nov 12 04:05 PM
Gottlieb Scott	Director	Nov 03 '25	Buy	122.13	500	61,065	12,523	Nov 05 04:05 PM
Dhingra Ankur	SVP, Chief Financial Officer	May 12 '25	Buy	81.21	6,100	495,381	24,906	May 14 04:20 PM
Thaysen Jacob	Chief Executive Officer	May 12 '25	Buy	80.88	6,500	525,732	77,540	May 14 04:18 PM
Thaysen Jacob	Chief Executive Officer	May 13 '25	Buy	80.84	5,850	472,942	83,390	May 14 04:18 PM
JAKOB WEDEL CHRISTENSEN	Officer	May 06 '25	Proposed Sale	77.21	549	42,388		May 06 04:02 PM
ARNOLD FRANCES	Director	Feb 27 '25	Proposed Sale	93.48	120	11,218		Feb 27 11:07 AM
JAKOB WEDEL	Officer	Feb 18 '25	Proposed Sale	100.00	460	46,000		Feb 18 04:22 PM
PATRICIA L LECKMAN	Officer	Feb 18 '25	Proposed Sale	100.00	1,756	175,600		Feb 18 04:08 PM

Open in Screener

TEM

Tempus AI Inc

Nov 25 • 04:00PM ET

76.84

+0.78 1.03 %

Healthcare • Health Information Services • USA • NASD

Peers: ILMN EXAS GH TXG CRSP PACB NTLA EDIT CDNA TWST

| Held by: ARKK VTI VB ARKG VBK VXF BAI IBB IWP JTEK

Index	-	P/E	-	EPS (ttm)	-1.18	Insider Own	42.91%	Shs Outstand	172.63M	Perf Week	15.08%
Market Cap	13.67B	Forward P/E	-	EPS next Y	-0.39	Insider Trans	-3.15%	Shs Float	101.58M	Perf Month	-16.10%
Enterprise Value	14.25B	PEG	-	EPS next Q	-0.04	Inst Own	47.27%	Short Float	20.98%	Perf Quarter	4.93%
Income	-203.88M	P/S	12.37	EPS this Y	61.52%	Inst Trans	11.37%	Short Ratio	2.79	Perf Half Y	44.44%
Sales	1.11B	P/B	26.88	EPS next Y	36.02%	ROA	-12.53%	Short Interest	21.31M	Perf YTD	127.61%
Book/sh	2.86	P/C	18.00	EPS next 5Y	-	ROE	-72.61%	52W High	104.32 -26.34%	Perf Year	46.42%
Cash/sh	4.27	P/FCF	-	EPS past 3/5Y	-37.97% -32.48%	ROIC	-11.13%	52W Low	31.36 145.03%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	39.06% 38.58%	Gross Margin	60.33%	Volatility	7.85% 6.49%	Perf 5Y	-
Dividend TTM	-	EV/Sales	12.89	EPS Y/Y TTM	76.81%	Oper. Margin	-21.07%	ATR (14)	5.16	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.12	Sales Y/Y TTM	72.58%	Profit Margin	-18.45%	RSI (14)	50.34	Recom	2.06
Dividend Gr. 3/5Y	- -	Current Ratio	3.28	EPS Q/Q	0.15%	SMA20	2.04%	Beta	5.04	Target Price	90.92
Payout	-	Debt/Eq	2.63	Sales Q/Q	84.72%	SMA50	-7.70%	Rel Volume	0.64	Prev Close	76.06
Employees	2400	LT Debt/Eq	2.61	Earnings	Nov 04 AMC	SMA200	15.13%	Avg Volume	7.63M	Price	76.84
IPO	Jun 14, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	36.16% 1.67%	Trades		Volume	4,880,323	Change	1.03%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-21-25	Downgrade	TD Cowen	Buy → Hold	$88
Oct-20-25	Initiated	Canaccord Genuity	Buy	$110
Sep-02-25	Initiated	H.C. Wainwright	Buy	$90
Apr-21-25	Initiated	BTIG Research	Buy	$60
Feb-25-25	Downgrade	JP Morgan	Overweight → Neutral	$50 → $55
Feb-12-25	Downgrade	William Blair	Outperform → Mkt Perform
Feb-05-25	Resumed	TD Cowen	Buy	$58 → $74
Dec-13-24	Initiated	Wolfe Research	Outperform	$60
Dec-09-24	Initiated	Guggenheim	Buy	$74
Nov-11-24	Downgrade	Stifel	Buy → Hold	$45 → $65
Oct-02-24	Downgrade	BofA Securities	Buy → Neutral	$45 → $60
Aug-12-24	Initiated	Piper Sandler	Neutral	$40
Jul-09-24	Initiated	William Blair	Outperform
Jul-09-24	Initiated	TD Cowen	Buy	$50
Jul-09-24	Initiated	Stifel	Buy	$45
Jul-09-24	Initiated	Needham	Buy	$47
Jul-09-24	Initiated	Morgan Stanley	Overweight	$44
Jul-09-24	Initiated	Loop Capital	Buy	$48
Jul-09-24	Initiated	Longbow	Buy	$48
Jul-09-24	Initiated	JP Morgan	Overweight	$42

Show Previous Ratings

Today 12:28PM	Hims & Hers Expands Care Scope as Digital Health Platforms Evolve (Zacks)
07:46AM	Tempus AI's Data Business Is Expanding and Adding to Revenues: Here's How (Zacks)
Nov-24-25 07:53AM	TEM vs. BFLY: Which Stock Offers Greater Upside Amid Health Tech Boom? (Zacks) +8.21%
Nov-18-25 08:30AM	Tempus to Participate in the Piper Sandler 37th Annual Healthcare Conference (Business Wire)
Nov-17-25 08:55AM	How Did Tempus AI Power Its Move to Positive EBITDA in Q3? (Zacks)
09:00AM	Loading…
Nov-15-25 09:00AM	Alphabets Secret Portfolio Just Bought These 2 Stocks. Should You Buy Too? (24/7 Wall St.)
Nov-14-25 12:03PM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
08:30AM	Tempus and IFLI Announce Study to Advance Follicular Lymphoma Research (Business Wire)
07:57AM	TEM Continues to Strengthen Its Genomics Leadership With New Products (Zacks)
Nov-11-25 07:29AM	Should You Buy, Hold or Sell TEM Stock Post Q3 Earnings Release? (Zacks)
Nov-09-25 10:00PM	Nancy Pelosi posted up a staggering 16,930% return on investment, beat the market by 581%: Here are her 5 biggest wins (Moneywise)
Nov-07-25 12:43PM	Hims & Hers Expands AI-Driven Personalized and Subscription-Based Care (Zacks)
10:15AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Nov-06-25 01:22PM	Tempus AI: Volatility Equates to Opportunity in AI Leader (MarketBeat) -12.36%
Nov-05-25 11:01AM	TEM's Q3 Earnings & Revenues Beat, Stock Down in After-Market Hours (Zacks)
08:30AM	Loading…
08:30AM	Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025 (Business Wire)
05:25AM	3 Growth Stocks to Invest $1,000 in Right Now (Motley Fool)
12:07AM	Tempus AI Inc (TEM) Q3 2025 Earnings Call Highlights: Strong Genomics Growth and Strategic ... (GuruFocus.com)
Nov-04-25 06:30PM	Tempus (TEM) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
05:45PM	Tempus AI (TEM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Tempus Reports Third Quarter 2025 Results (Business Wire)
06:01AM	Sex Dolls, Boycotts, Protests: Furor in France as Shein Opens Paris Store (The Wall Street Journal)
Nov-03-25 04:36PM	Sex Dolls, Boycotts, Protests: Furor in France as Shein Opens Paris Store (The Wall Street Journal)
07:19AM	Tempus AI Inc (TEM) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-31-25 10:46AM	This AI Health Stock is Up Over 150% This Yearand Its Not Slowing Down (24/7 Wall St.)
Oct-30-25 07:45AM	Omnicell (OMCL) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Oct-29-25 08:57AM	TEM vs. EXAS: Which Genomics Player Offers Greater Upside? (Zacks)
Oct-28-25 08:30AM	Tempus to Participate in the Stifel 2025 Healthcare Conference (Business Wire) -5.45%
05:53AM	Tempus AI (TEM) Stock Gets a $110 Price Target on Rising AI Adoption in Medicine (Insider Monkey)
Oct-27-25 09:20AM	Tempus AI Enhances AI-Driven Diagnostics With Multiple FDA Approvals (Zacks)
09:47AM	Loading…
Oct-21-25 09:47AM	Tempus AI valuation catches up with its growth, says TD Cowen downgrading stock (Investing.com)
09:32AM	Goldman downgraded, Coinbase initiated: Wall Street's top analyst calls (The Fly)
08:30AM	Tempus to Report Third Quarter 2025 Financial Results on November 4 (Business Wire)
Oct-20-25 06:36PM	Why Tempus AI Stock Raced More Than 5% Higher Today (Motley Fool) +5.32%
04:56PM	These Stocks Moved the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More (Barrons.com)
09:34AM	Apple upgraded, Rivian downgraded: Wall Street's top analyst calls (The Fly)
09:03AM	Tempus AI Stock Before Q3 Earnings Release: To Buy or Not to Buy? (Zacks)
09:00AM	Ambry Genetics Announces 10-Year Study in Genetics in Medicine Highlighting the Impact of Proactive Exome Reanalysis for Healthcare Equity (Business Wire)
Oct-17-25 09:45AM	Tempus AI Fuels Growth Through Strategic Biotech Collaborations (Zacks)
Oct-16-25 12:36PM	Hims & Hers Elevates Technology-Driven Healthcare Accessibility (Zacks)
08:30AM	Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research (Business Wire)
Oct-15-25 01:49PM	Tempus AI Hits $100-Are Shares Due for a Pullback? (MarketBeat)
08:30AM	Tempus Announces Six Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025 (Business Wire)
Oct-14-25 03:00PM	NVDA & PLTR Driving AI in Health: Top Health IT Stocks for Q3 Earnings (Zacks)
Oct-10-25 08:44AM	TEM Expands Partnership With Northwestern Medicine Amid AI Boom (Zacks)
Oct-09-25 10:54AM	Strategic Deals Drive TEM Growth Amid Competition: Buy, Hold or Sell? (Zacks)
08:30AM	Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy (Business Wire)
Oct-08-25 05:48PM	These 5 Beaten-Down Tech Stocks Could Catch Fire Next (MarketBeat) +11.01%
11:22AM	Tempus AI, Inc. (TEM): A Bull Case Theory (Insider Monkey)
10:58AM	Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034 (PR Newswire)
Oct-05-25 02:42AM	Tempus AI, Inc. (TEM) Secures FDA Clearance for xR IVD Device to Enhance Drug Discovery (Insider Monkey)
Oct-03-25 05:30AM	Why Tempus AI Stock Was Motoring Higher This Week (Motley Fool)
Oct-01-25 12:24PM	Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density (Business Wire) +9.02%
Sep-27-25 11:13AM	3 Healthcare Stocks Using AI to Drive Growth (MarketBeat)
08:45AM	What Are 2 Great Tech Stocks to Buy Right Now? (Motley Fool)
Sep-26-25 09:21AM	TEM vs. ILMN: Which Precision Oncology Stock Is Worth Buying Now? (Zacks)
Sep-25-25 06:53PM	Why Tempus AI Stock Is Plunging This Week (Motley Fool)
Sep-23-25 08:32AM	Tempus AI Enhances Cancer Research Tools With FDA-Cleared xR IVD (Zacks)
Sep-22-25 04:07PM	IBD 50's Tempus AI Pulls Back From Record High After Another FDA Clearance (Investor's Business Daily)
12:45PM	Hims & Hers Expands Care Ecosystem via Global and Digital Innovation (Zacks)
10:04AM	IBD 50's Tempus AI Hits Record High On Yet Another FDA Clearance (Investor's Business Daily)
09:00AM	3 Big Short Interest Names with Bullish Setups (MarketBeat)
08:30AM	Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device (Business Wire)
Sep-21-25 09:30AM	Tempus AI Surges Since IPO as FDA Clearance Boosts Growth Outlook (Insider Monkey)
Sep-18-25 08:45AM	Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises (PR Newswire)
Sep-16-25 08:20AM	TEM Strengthens Radiology Portfolio With Pixel's FDA Clearance (Zacks)
Sep-15-25 08:00AM	Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease (PR Newswire)
Sep-12-25 09:42AM	Tempus AI (TEM) Touches 7-Month High on Pixel FDA Approval (Insider Monkey)
08:43AM	Tempus (TEM) Stock Jumps 13.6%: Will It Continue to Soar? (Zacks)
Sep-11-25 06:26PM	Why Tempus AI Stock Soared Nearly 14% Higher Today (Motley Fool) +13.59%
05:01PM	Northwestern Medicine Integrates Tempus AI's "David" Clinical Assistant into EHR Platform (Insider Monkey)
01:58PM	Tempus AI Gains FDA Clearance For Updated Pixel To Boost Accuracy And Efficiency In Cardiac Imaging (Benzinga)
11:11AM	Tempus AI Surges, Flirting With A Profit-Taking Zone, On A Fresh FDA Move (Investor's Business Daily)
08:35AM	TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape (Zacks)
08:30AM	Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device (Business Wire)
Sep-09-25 08:44AM	TEM Q2 Revenues Soar Amid Coverage Issues: Time to Buy, Hold or Sell? (Zacks)
08:30AM	Tempus Announces New Study in JCO Precision Oncology Validating PurIST Algorithm for Enhanced Therapy Selection in Pancreatic Cancer (Business Wire)
Sep-04-25 12:30PM	What's Fueling Tempus AI's Q2 Net Loss Improvement Momentum? (Zacks)
08:30AM	Northwestern Medicine Becomes First Health System to Integrate Tempus' Generative AI Co-Pilot, David, Into Its EHR Platform (Business Wire)
Sep-03-25 04:01PM	Tempus to Participate in Morgan Stanleys 23rd Annual Global Healthcare Conference (Business Wire)
Sep-02-25 10:40AM	3 Heavily Shorted Stocks That Could Prove the Bears Wrong (MarketBeat)
09:45AM	Elf Beauty downgraded, Zscaler upgraded: Wall Street's top analyst calls (The Fly)
Aug-29-25 11:42PM	Tempus AI, Inc. (TEM) Expands into Digital Pathology with Paige Acquisition (Insider Monkey)
04:36PM	Tempus AI Stock Required A Tempered Position (Investor's Business Daily)
Aug-27-25 10:44AM	Hims & Hers Scales Growth Through Subscriptions and Care Expansion (Zacks)
Aug-26-25 08:42AM	Tempus' Key Acquisitions Strengthen Its AI Healthcare Leadership (Zacks)
06:00AM	Tempus inks $81M Paige buyout to support AI model development (MedTech Dive)
Aug-25-25 03:00PM	Tempus AI or Butterfly: Which AI Health Tech Stock is a Buy Now? (Zacks) -5.74%
10:30AM	BC-Most Active Stocks (Associated Press Finance)
09:12AM	Zacks Market Edge Highlights: ARKK, Tesla, Palantir Technologies, Robinhood Markets and Tempus (Zacks)
05:02AM	Tempus to acquire AI digital pathology company Paige (Medical Device Network)
12:21AM	TD Cowen Lifts Tempus AI (TEM) Price Target on Genomic Volumes Growth (Insider Monkey)
Aug-23-25 04:00AM	The Next Big Thing: 2 AI-Powered Healthcare Stocks Ready to Explode (Motley Fool)
Aug-22-25 02:38PM	Tempus AI Expands Into Digital Pathology With Paige Acquisition (Benzinga)
09:20AM	Tempus Announces the Acquisition of Paige (Business Wire)
08:02AM	4 Medical Devices Behemoths to Buy Amid Extensive AI Applications (Zacks)
Aug-21-25 07:11PM	Cathie Wood's ARKK ETF is Back: Buy It or Not? (Zacks)
Aug-20-25 11:47AM	5 High Short-Interest Stocks to Buy Before November (MarketBeat)
Aug-19-25 09:33AM	Strategic Partnerships Power Tempus AI's Healthcare Expansion (Zacks) -6.85%
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +6.33%

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LEFKOFSKY ERIC P	CEO and Chairman	Nov 24 '25	Sale	74.10	166,250	12,319,125	9,008,033	Nov 25 04:30 PM
Polovin Andrew	EVP and General Counsel	Nov 24 '25	Sale	75.00	12,874	965,550	107,590	Nov 25 04:30 PM
Eric Lefkofsky	Officer	Nov 20 '25	Proposed Sale	70.40	166,250	11,703,285		Nov 24 06:11 PM
ANDREW POLOVIN	Officer	Nov 24 '25	Proposed Sale	70.29	12,874	904,913		Nov 24 04:29 PM
LEFKOFSKY ERIC P	CEO and Chairman	Nov 20 '25	Sale	68.97	166,250	11,466,099	9,041,283	Nov 20 07:56 PM
LEFKOFSKY ERIC P	CEO and Chairman	Nov 18 '25	Sale	65.54	16,829	1,102,944	2,003,213	Nov 20 07:56 PM
Rogers James William	Chief Financial Officer	Nov 18 '25	Sale	65.54	7,257	475,611	131,216	Nov 20 07:05 PM
Polovin Andrew	EVP and General Counsel	Nov 19 '25	Sale	68.06	6,387	434,707	120,464	Nov 20 07:05 PM
Polovin Andrew	EVP and General Counsel	Nov 18 '25	Sale	65.54	5,205	341,126	126,851	Nov 20 07:05 PM
Phelps Erik	EVP & Chief Admin & Legal Off	Nov 18 '25	Sale	65.54	3,533	231,547	90,582	Nov 20 07:05 PM
Fukushima Ryan	Chief Operating Officer	Nov 18 '25	Sale	65.54	10,099	661,870	829,081	Nov 20 07:05 PM
Bartolucci Ryan M	Chief Accounting Officer	Nov 18 '25	Sale	65.54	1,834	120,197	44,061	Nov 20 07:05 PM
Eric Lefkofsky	Officer	Nov 20 '25	Proposed Sale	69.09	166,250	11,486,212		Nov 20 04:46 PM
ANDREW POLOVIN	Officer	Nov 19 '25	Proposed Sale	66.77	6,387	426,460		Nov 19 04:22 PM
Ryan M. Bartolucci	Officer	Nov 18 '25	Proposed Sale	66.39	1,834	121,759		Nov 18 07:09 PM
Ryan Fukushima	Officer	Nov 18 '25	Proposed Sale	66.39	10,099	670,473		Nov 18 07:08 PM
Eric Paul Lefkofsky	Officer	Nov 18 '25	Proposed Sale	66.39	16,829	1,117,277		Nov 18 07:07 PM
Andrew Polovin	Officer	Nov 18 '25	Proposed Sale	66.39	5,205	345,560		Nov 18 07:05 PM
James William Rogers	Officer	Nov 18 '25	Proposed Sale	66.39	7,257	481,792		Nov 18 07:04 PM
Erik Phelps	Officer	Nov 18 '25	Proposed Sale	66.39	3,533	234,556		Nov 18 07:03 PM
Doudna Jennifer A	Director	Nov 11 '25	Sale	71.45	1,926	137,613	24,628	Nov 13 04:15 PM
JENNIFER DOUDNA	Director	Nov 11 '25	Proposed Sale	71.78	3,852	276,497		Nov 12 07:03 AM
Fukushima Ryan	Chief Operating Officer	Nov 03 '25	Sale	89.03	5,000	445,160	125,000	Nov 05 04:15 PM
Epstein David R	Director	Nov 03 '25	Sale	90.00	370	33,300	26,671	Nov 05 04:15 PM
VANESSA L KUBO	Officer	Nov 03 '25	Proposed Sale	89.85	20,000	1,797,000		Nov 03 04:26 PM
DAVID R. EPSTEIN	Director	Nov 03 '25	Proposed Sale	89.85	990	88,952		Nov 03 04:25 PM
LEFKOFSKY ERIC P	CEO and Chairman	Oct 28 '25	Sale	89.11	332,500	29,629,006	9,074,532	Oct 30 04:31 PM
Eric Lefkofsky	Officer	Oct 28 '25	Proposed Sale	91.58	332,500	30,450,350		Oct 28 04:09 PM
Fukushima Ryan	Chief Operating Officer	Oct 06 '25	Sale	92.32	5,000	461,606	130,000	Oct 08 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Sep 25 '25	Sale	76.56	332,500	25,457,014	9,141,032	Sep 29 04:33 PM
Eric Lefkofsky	Officer	Sep 25 '25	Proposed Sale	84.13	332,500	27,973,225		Sep 25 07:04 PM
Fukushima Ryan	Chief Operating Officer	Sep 02 '25	Sale	75.80	10,000	758,028	135,000	Sep 04 04:15 PM
Epstein David R	Director	Sep 02 '25	Sale	73.64	250	18,410	27,041	Sep 04 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Aug 27 '25	Sale	74.10	332,500	24,637,581	9,207,533	Aug 29 05:13 PM
Leonsis Theodore	Director	Aug 26 '25	Sale	75.83	20,000	1,516,600	66,756	Aug 28 04:15 PM
Eric Lefkofsky	Officer	Aug 27 '25	Proposed Sale	75.90	332,500	25,236,750		Aug 27 04:19 PM
Leonsis Theodore	Director	Aug 26 '25	Proposed Sale	75.83	20,000	1,516,650		Aug 26 01:27 PM
Polovin Andrew	EVP and General Counsel	Aug 19 '25	Sale	74.65	5,398	402,982	132,056	Aug 21 04:15 PM
Phelps Erik	EVP & Chief Admin & Legal Off	Aug 19 '25	Sale	74.65	3,664	273,532	94,115	Aug 21 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Aug 19 '25	Sale	74.65	17,458	1,303,307	2,020,042	Aug 21 04:15 PM
Fukushima Ryan	Chief Operating Officer	Aug 19 '25	Sale	74.65	17,460	1,303,456	839,180	Aug 21 04:15 PM
Rogers James William	Chief Financial Officer	Aug 19 '25	Sale	74.65	7,528	561,994	138,473	Aug 21 04:15 PM
Bartolucci Ryan M	Chief Accounting Officer	Aug 19 '25	Sale	74.65	1,904	142,141	45,895	Aug 21 04:15 PM
Erik Phelps	Officer	Aug 19 '25	Proposed Sale	78.45	3,664	287,441		Aug 20 07:19 AM
Andrew Polovin	Officer	Aug 19 '25	Proposed Sale	78.45	5,398	423,473		Aug 20 07:17 AM
Ryan Fukushima	Officer	Aug 19 '25	Proposed Sale	78.45	17,460	1,369,737		Aug 20 07:15 AM
Eric Paul Lefkofsky	Officer	Aug 19 '25	Proposed Sale	78.45	17,458	1,369,580		Aug 20 07:14 AM
James William Rogers	Officer	Aug 19 '25	Proposed Sale	78.45	7,528	590,572		Aug 19 09:59 PM
Ryan M. Bartolucci	Officer	Aug 19 '25	Proposed Sale	78.45	1,904	149,369		Aug 19 09:56 PM
Leonsis Theodore	Director	Aug 13 '25	Proposed Sale	69.90	44,000	3,075,786		Aug 18 02:44 PM
Leonsis Theodore	Director	Aug 13 '25	Sale	69.90	44,000	3,075,600	86,756	Aug 15 09:21 PM
Epstein David R	Director	Aug 01 '25	Sale	55.16	370	20,409	27,291	Aug 05 04:15 PM
DAVID R. EPSTEIN	Director	Aug 01 '25	Proposed Sale	56.59	620	35,086		Aug 01 04:30 PM
LEFKOFSKY ERIC P	CEO and Chairman	Jul 28 '25	Sale	62.87	166,250	10,452,027	9,274,033	Jul 30 08:42 PM
Eric Lefkofsky	Officer	Jul 28 '25	Proposed Sale	64.49	166,250	10,721,462		Jul 28 04:13 PM
Fukushima Ryan	Chief Operating Officer	Jul 07 '25	Sale	60.00	5,000	300,000	145,000	Jul 09 04:15 PM
VANESSA L KUBO	Officer	Jul 07 '25	Proposed Sale	60.97	20,000	1,219,400		Jul 07 04:16 PM
Doudna Jennifer A	Director	Jul 01 '25	Sale	62.52	625	39,075	26,554	Jul 03 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Jun 17 '25	Sale	70.07	250,000	17,516,593	9,357,283	Jun 20 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Jun 18 '25	Sale	69.44	250,000	17,359,469	9,307,283	Jun 20 04:15 PM
Phelps Erik	EVP & Chief Admin & Legal Off	Jun 16 '25	Sale	72.56	51,317	3,723,634	97,779	Jun 18 04:15 PM
Polovin Andrew	EVP and General Counsel	Jun 16 '25	Sale	72.13	1,423	102,641	137,454	Jun 18 04:15 PM
Eric Paul Lefkofsky	Officer	Jun 17 '25	Proposed Sale	72.00	400,000	28,800,000		Jun 17 09:45 PM
ERIK PHELPS	Officer	Jun 16 '25	Proposed Sale	71.28	51,317	3,657,876		Jun 16 04:30 PM
ANDREW POLOVIN	Officer	Jun 16 '25	Proposed Sale	71.28	1,423	101,431		Jun 16 04:22 PM
Leonsis Theodore	Director	Jun 11 '25	Sale	67.66	205,847	13,927,976	0	Jun 13 04:15 PM
Revolution Growth Management C	Shareholder	Jun 11 '25	Proposed Sale	69.38	205,847	14,281,665		Jun 11 04:02 PM
Fukushima Ryan	Chief Operating Officer	Jun 03 '25	Sale	62.29	20,000	1,245,764	856,640	Jun 05 04:15 PM
Doudna Jennifer A	Director	Jun 02 '25	Sale	55.20	558	30,802	27,179	Jun 04 04:15 PM
Epstein David R	Director	Jun 02 '25	Sale	55.20	250	13,800	27,661	Jun 04 04:15 PM
JENNIFER A DOUDNA	Director	Jun 02 '25	Proposed Sale	55.18	1,183	65,278		Jun 02 04:32 PM
Rogers James William	Chief Financial Officer	May 20 '25	Sale	63.27	23,121	1,462,809	146,001	May 22 08:00 PM
Polovin Andrew	EVP and General Counsel	May 20 '25	Sale	63.43	17,552	1,113,385	138,877	May 22 08:00 PM
Phelps Erik	EVP & Chief Admin & Legal Off	May 20 '25	Sale	63.21	8,415	531,918	149,096	May 22 08:00 PM
LEFKOFSKY ERIC P	CEO and Chairman	May 20 '25	Sale	63.21	16,752	1,058,905	4,878,837	May 22 08:00 PM
Fukushima Ryan	Chief Operating Officer	May 20 '25	Sale	63.21	7,820	494,308	876,640	May 22 08:00 PM
Bartolucci Ryan M	Chief Accounting Officer	May 20 '25	Sale	63.23	6,073	384,023	47,799	May 22 08:00 PM
Ryan M. Bartolucci	Officer	May 20 '25	Proposed Sale	63.74	4,254	271,150		May 21 07:39 PM
Ryan Fukushima	Officer	May 20 '25	Proposed Sale	63.74	7,820	498,447		May 21 07:36 PM
Andrew Polovin	Officer	May 20 '25	Proposed Sale	63.74	9,797	624,461		May 21 07:25 PM
Eric Paul Lefkofsky	Officer	May 20 '25	Proposed Sale	63.74	16,752	1,067,772		May 21 07:23 PM
Erik Phelps	Officer	May 20 '25	Proposed Sale	63.74	8,415	536,372		May 21 07:20 PM
James William Rogers	Officer	May 20 '25	Proposed Sale	63.74	11,413	727,465		May 21 07:18 PM
RYAN BARTOLUCCI	Officer	May 20 '25	Proposed Sale	63.74	1,819	115,943		May 20 04:32 PM
ANDREW POLOVIN	Officer	May 20 '25	Proposed Sale	63.74	7,755	494,304		May 20 04:31 PM
JAMES ROGERS	Officer	May 20 '25	Proposed Sale	63.74	11,708	746,268		May 20 04:31 PM
Leonsis Theodore	Director	May 09 '25	Sale	66.26	770	51,020	43,550	May 13 04:15 PM
REVOLUTION GROWTH III, LP	Shareholder	May 09 '25	Proposed Sale	65.22	770	50,219		May 09 04:18 PM
Fukushima Ryan	Chief Operating Officer	May 06 '25	Sale	52.36	20,000	1,047,239	884,460	May 08 04:30 PM
Epstein David R	Director	May 01 '25	Sale	53.50	370	19,795	25,914	May 05 04:15 PM
Gottlieb Scott	Director	Apr 01 '25	Sale	47.21	27,837	1,314,154	32,839	Apr 03 05:30 PM
Doudna Jennifer A	Director	Apr 01 '25	Sale	48.12	625	30,075	25,740	Apr 03 04:15 PM
Fukushima Ryan	Chief Operating Officer	Apr 01 '25	Sale	47.20	20,000	944,085	904,460	Apr 03 04:15 PM
Frederick Wayne A.I.	Director	Mar 31 '25	Sale	45.54	3,000	136,620	26,514	Apr 02 06:13 PM
RYAN FUKUSHIMA	Officer	Apr 01 '25	Proposed Sale	48.24	60,000	2,894,400		Apr 01 04:22 PM
Polovin Andrew	EVP and General Counsel	Mar 21 '25	Sale	50.00	3,076	153,800	151,095	Mar 25 04:15 PM
ANDREW POLOVIN	Officer	Mar 21 '25	Proposed Sale	48.04	3,076	147,771		Mar 21 04:21 PM
Rogers James William	Chief Financial Officer	Mar 18 '25	Sale	45.97	23,030	1,058,699	164,750	Mar 19 06:30 PM
Polovin Andrew	EVP and General Counsel	Mar 18 '25	Sale	45.98	13,135	603,970	154,171	Mar 19 06:30 PM
Epstein David R	Director	Mar 17 '25	Sale	46.83	990	46,362	26,284	Mar 19 06:30 PM

Open in Screener

PFE

Pfizer Inc

Nov 25 • 04:00PM ET

25.72

+0.50 1.98 %

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: BMY MRK SNY AMGN ABBV NVS JNJ GSK LLY AZN

| Held by: VTI VOO IVV SPY VTV XLV VYM VHT DVY FDL

Index	S&P 500	P/E	14.99	EPS (ttm)	1.72	Insider Own	0.09%	Shs Outstand	5.69B	Perf Week	1.06%
Market Cap	146.24B	Forward P/E	8.31	EPS next Y	3.09	Insider Trans	0.00%	Shs Float	5.68B	Perf Month	3.84%
Enterprise Value	193.26B	PEG	-	EPS next Q	0.60	Inst Own	66.75%	Short Float	2.23%	Perf Quarter	2.59%
Income	9.80B	P/S	2.33	EPS this Y	0.57%	Inst Trans	-0.17%	Short Ratio	1.88	Perf Half Y	10.96%
Sales	62.78B	P/B	1.58	EPS next Y	-1.04%	ROA	4.58%	Short Interest	126.59M	Perf YTD	-3.05%
Book/sh	16.32	P/C	9.76	EPS next 5Y	-1.40%	ROE	10.59%	52W High	27.69 -7.11%	Perf Year	2.35%
Cash/sh	2.64	P/FCF	14.09	EPS past 3/5Y	-28.69% -13.27%	ROIC	6.52%	52W Low	20.92 22.97%	Perf 3Y	-46.67%
Dividend Est.	1.70 (6.61%)	EV/EBITDA	7.32	Sales past 3/5Y	-7.84% 9.10%	Gross Margin	69.53%	Volatility	2.81% 2.68%	Perf 5Y	-29.19%
Dividend TTM	1.72 (6.69%)	EV/Sales	3.08	EPS Y/Y TTM	128.96%	Oper. Margin	31.40%	ATR (14)	0.66	Perf 10Y	-17.43%
Dividend Ex-Date	Nov 07, 2025	Quick Ratio	0.97	Sales Y/Y TTM	4.44%	Profit Margin	15.60%	RSI (14)	57.84	Recom	2.37
Dividend Gr. 3/5Y	2.49% 2.97%	Current Ratio	1.28	EPS Q/Q	-20.96%	SMA20	3.19%	Beta	0.41	Target Price	29.01
Payout	120.11%	Debt/Eq	0.66	Sales Q/Q	-5.92%	SMA50	3.29%	Rel Volume	0.58	Prev Close	25.22
Employees	81000	LT Debt/Eq	0.62	Earnings	Nov 04 BMO	SMA200	4.73%	Avg Volume	67.17M	Price	25.72
IPO	Jan 17, 1944	Option/Short	Yes / Yes	EPS/Sales Surpr.	37.53% 0.94%	Trades		Volume	38,953,715	Change	1.98%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-13-25	Initiated	Scotiabank	Sector Outperform	$30
Apr-22-25	Initiated	Cantor Fitzgerald	Neutral	$24
Dec-10-24	Resumed	BofA Securities	Neutral	$29
Nov-15-24	Initiated	Wolfe Research	Underperform	$25
Oct-25-24	Resumed	Citigroup	Neutral	$30
Oct-17-24	Initiated	Bernstein	Mkt Perform	$32
Aug-07-24	Upgrade	Daiwa Securities	Neutral → Outperform
Mar-22-24	Downgrade	Argus	Buy → Hold
Feb-23-24	Initiated	Guggenheim	Buy	$36
Jan-04-24	Downgrade	TD Cowen	Outperform → Market Perform	$32
Oct-20-23	Resumed	UBS	Neutral	$36 → $34
Oct-16-23	Upgrade	Jefferies	Hold → Buy	$38 → $39
Jul-17-23	Reiterated	JP Morgan	Neutral	$45 → $41
Jul-14-23	Initiated	HSBC Securities	Buy	$50
Jun-29-23	Downgrade	Credit Suisse	Outperform → Neutral	$47 → $40
May-11-23	Downgrade	Daiwa Securities	Outperform → Neutral	$38
Mar-06-23	Initiated	Jefferies	Hold	$43
Feb-07-23	Upgrade	Daiwa Securities	Neutral → Outperform	$51
Jan-26-23	Downgrade	UBS	Buy → Neutral	$55 → $47
Jan-17-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$54 → $50

Show Previous Ratings

Today 07:22PM	U.S. Negotiates Lower Prices for Ozempic and 14 Other Drugs (The Wall Street Journal)
12:28PM	FDA Decision Opens Bigger Market for Novartis's Blockbuster Gene Therapy (Barrons.com)
09:47AM	Novo Nordisk Drug Helps Patients Lose Weight, Lower Blood Sugar in Trial (The Wall Street Journal)
08:16AM	Jim Cramer on Pfizer: "I Think It Can Be Near a Breakout" (Insider Monkey)
07:24AM	J&J Up Around 17% in 3 Months: Should You Buy, Sell or Hold the Stock? (Zacks)
06:30AM	Loading…
06:30AM	Bayer Resurrects Scrapped Blood-Thinning Drug as Breakthrough Stroke Treatment (The Daily Upside)
06:24AM	Is This the Best Value Stock to Buy While Markets Are Volatile? (Motley Fool)
05:30AM	Want Over $7,000 in Annual Dividends? Invest $25,000 in Each of These 4 Stocks. (Motley Fool)
03:00AM	4 takeaways from pharmas manufacturing boom (Pharma Voice)
Nov-24-25 04:11PM	Bristol Myers Pops On A 'Surprisingly Positive' Update From Key Rival Bayer (Investor's Business Daily)
03:40PM	Mamdani Taps Ex-Goldman Partner, Developer for Transition Team (Bloomberg)
12:30PM	Moderna is the S&P 500's most shorted stock: Here's why (Yahoo Finance Video)
11:46AM	Novo's $5 Billion Alzheimer's Dream Just Died--And Investors Are Cratering the Stock (GuruFocus.com)
10:50AM	FDA Approves MRK's Keytruda & Keytruda SC Combo in Bladder Cancer (Zacks)
08:16AM	Lilly Crosses $1 Trillion Market Cap: Here's What Is Driving the Rally (Zacks)
09:20AM	Loading…
Nov-22-25 09:20AM	2 Healthcare Stocks for Beginner Investors With a 20-Year Time Horizon (Motley Fool)
Nov-21-25 06:55PM	Pfizer, UnitedHealth, Viatris, Addus HomeCare, and Quest Stocks Trade Up, What You Need To Know (StockStory)
02:37PM	Fighting Cancer With 'Smart Bombs.' What New Treatments Mean For Wall Street. (Investor's Business Daily)
01:24PM	U.S. FDA Approves PADCEV plus Keytruda for Certain Patients with Bladder Cancer (Business Wire)
09:34AM	The Great S&P 500 Shakeup Leaves Microsoft and Oracle the Last Giants Standing (24/7 Wall St.)
09:00AM	Is Trending Stock Pfizer Inc. (PFE) a Buy Now? (Zacks)
08:00AM	This 7%-Yielding Dividend Stock Is About to Enter an Exciting New Phase (Motley Fool)
07:41AM	PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms (Zacks)
04:25AM	Goldman Sachs Just Delivered Bad News for U.S. Investors ... Sort Of. Here's What You Need to Know. (Motley Fool)
Nov-20-25 02:08PM	Pfizer and Tris reach settlement with Texas over ADHD drug allegations (Pharmaceutical Business Review)
01:10PM	Will Librexia ACS Study Setback Dent BMY's Cardiovascular Portfolio? (Zacks)
11:30AM	VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug (Zacks)
10:15AM	Wall Street Gives Up on High-Yield Stocks (24/7 Wall St.)
09:30AM	Is Pfizer's 6.9%-Yielding Dividend Still Safe? (Motley Fool)
08:00AM	This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy. (Barrons.com)
06:30AM	Loading…
06:30AM	White House Touts $270 Billion Worth of Deals at Saudi-palooza (The Daily Upside)
06:22AM	Pfizer and Tris agree with Texas over ADHD drug allegations (Pharmaceutical Business Review)
Nov-19-25 09:42PM	Pfizer Is Giving Up on BioNTech. Should You Ditch BNTX Stock Now Too? (Barchart)
05:27PM	HIMS Has Been a Roller Coaster Ride. Should Investors Hop On? (MarketBeat)
11:30AM	A Sickle Cell Trial Delivers Mixed Results. Agios Stock Falls by 48%. (Barrons.com)
11:00AM	Pfizer CEO on plans to bring down drug prices (Yahoo Finance Video)
10:38AM	Why GRAIL Stock Could Be Biotech's Next Big Breakout (MarketBeat)
03:39AM	Business Leaders Set to Welcome Saudi Investments after a Combative White House Meeting (Barrons.com)
Nov-18-25 09:22PM	Elon Musk, Jensen Huang to talk AI at US-Saudi investment forum (Reuters)
04:21PM	Why biotech and drug stocks are on the mend even though the rest of the market is hurting (MarketWatch)
03:33PM	Novo Nordisk, Eli Lilly Weight Loss Price War Heats Up. Why Its a Worry for the Stocks. (Barrons.com)
02:23PM	Can AI Drive Peloton's Comeback? (Motley Fool)
11:03AM	J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B (Zacks)
10:59AM	Pfizer Trading Above 50-Day SMA: Is it a Good Time to Buy the Stock? (Zacks)
06:45AM	2 No-Brainer Healthcare Stocks to Buy Now (Motley Fool)
06:24AM	Nuvalent aiming for approval on pivotal trial data for NSCLC candidate (Clinical Trials Arena)
05:30AM	The Weight-Loss Craze Is About to Mint a Trillion-Dollar Company (The Wall Street Journal)
Nov-17-25 10:31PM	Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Pfizer (NYSE:PFE) (StockStory)
09:10PM	Pfizer's CEO Sends a Warning to Eli Lilly. Is the Stock a Buy? (Motley Fool)
04:41PM	Johnson & Johnson Inks A $3.05 Billion Deal In Cancer Treatment (Investor's Business Daily)
01:20PM	Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion (Barrons.com)
10:00AM	2 Giant Healthcare Stocks to Buy Hand Over Fist in November (Motley Fool)
08:33AM	MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026 (Zacks)
05:25AM	This Sector Is Suddenly Crushing the Broader Market. Should You Invest $1,000? (Motley Fool)
04:35AM	Down 55%, Should You Buy the Dip on Pfizer? (Motley Fool)
Nov-15-25 12:30PM	Values that Pfizer and Delta CEOs draw on for great leadership (Yahoo Finance)
05:45AM	Is Pfizer Stock a Buy After This $10 Billion Acquisition? (Motley Fool)
Nov-14-25 01:02PM	Eli Lilly Strikes Deal With Trump: Why Shares Are Up 10% Since (MarketBeat)
12:39PM	Health Care Roundup: Market Talk (The Wall Street Journal)
11:38AM	To Wall Street, a new bidding war puts Alkermes in a tough spot (BioPharma Dive)
11:36AM	Why Pfizer (PFE) Shares Are Sliding Today (StockStory)
10:53AM	Novo Chairman Blames Board Dropout on Former Employer Pfizer (Bloomberg)
09:37AM	Merck agrees $9.2bn deal for flu-prevention biotech Cidara (Financial Times)
07:59AM	Pharma ETFs in Spotlight Following Robust Q3 Earnings Results (Zacks)
06:41AM	Pfizer Cuts BioNTech Stake by More Than Half (GuruFocus.com)
06:06AM	Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal (BioPharma Dive)
03:00AM	Is that pharma influencer human or AI? (Pharma Voice)
Nov-13-25 03:12PM	Pfizer CEO says RFK Jr. wasn't his 'first choice' for HHS Secretary (Yahoo Finance)
02:38PM	Pfizer completes Metsera acquisition in deal worth up to $10 bn (AFP)
02:30PM	RFK Jr. would not have been my HHS pick: Pfizer CEO (Yahoo Finance Video)
02:20PM	Healthcare Stocks Are Blowing Past the S&P 500. What Could Be Behind the Rally. (Barrons.com)
01:58PM	Activist investor Jeff Smith: How Starboard 'lights a fire' under Corporate America (Yahoo Finance)
01:45PM	BMY's Growth Portfolio Shines in Q3: Turning Point Ahead? (Zacks)
01:24PM	Pfizer Dumps BioNTech Stake as Obesity Gold Rush Heats Up (GuruFocus.com)
01:15PM	Future of medicine will be profoundly impacted by AI: Pfizer CEO (Yahoo Finance Video)
12:14PM	Pfizer CEO Albert Bourla says aggressive bid for Metsera reflects company's 'right to win' obesity market (Yahoo Finance)
12:04PM	Pfizer CEO: AI will help with medicine's next big breakthrough (Yahoo Finance Video)
11:58AM	Pfizer plans to enter GLP-1 space by 2028, CEO explains (Yahoo Finance Video)
11:26AM	Pfizer Completes Acquisition of Metsera (Business Wire)
09:45AM	Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls (The Fly)
07:01AM	Inside Yahoo Finance Invest 2025: Elon Musk's $1 trillion pay package, crypto cracks, and AI bubbles (Yahoo Finance)
06:23AM	CPHI 2025: handprint metric bridges pharma sustainability and economic value (Pharmaceutical Technology)
04:55AM	Should You Forget Pfizer and Buy This Magnificent Drug Stock Instead? (Motley Fool)
Nov-12-25 08:27PM	3 Healthcare Stocks Topping a 2025 List of Dividend Yields (Motley Fool)
01:47PM	The FDA Has a New Drug Chief. What it Means for Biotech Stocks. (Barrons.com)
12:10PM	Jim Cramer Finds Pfizer (PFE)'s Stock Level "Unfathomable" (Insider Monkey)
10:31AM	Pfizer: Could AI unlock new value for drug makers? (Yahoo Finance Video)
10:15AM	2 Strong Healthcare Stock Picks for Value Investors (Motley Fool)
10:00AM	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Business Wire)
08:46AM	Healthcare breakout means investors should add exposure to the sector, says Strategas (MarketWatch)
04:35AM	Why Metsera's Share Price Is Plummeting This Week (Motley Fool)
Nov-11-25 09:55PM	TD Cowen Maintains a Hold on Pfizer Inc. (PFE) With a $30 PT (Insider Monkey)
07:47PM	Analyst Report: Viatris Inc. (Morningstar Research)
03:55PM	Pfizer, Amneal, Jazz Pharmaceuticals, BD, and DaVita Shares Skyrocket, What You Need To Know (StockStory)
02:34PM	Jim Cramer Says "I Think Pfizer's Very Smart to Buy Metsera" (Insider Monkey)
02:30PM	Why Metsera is 'in better hands' with Pfizer than Novo Nordisk (Yahoo Finance Video)
11:30AM	Markets exhale as Novo Nordisk withdraws from Metsera bidding war (Euronews)
10:53AM	5 Highest Yielding Dividend Stocks in the S&P 500 (24/7 Wall St.)
10:07AM	Where Will Pfizer Be in 3 Years? (Motley Fool)
05:30AM	Obesity Drugs Are About to Go Mass-Market (The Wall Street Journal)

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dolsten Mikael	Former Officer	May 23 '25	Proposed Sale	23.09	59,781	1,380,632		May 23 10:54 AM
Dolsten Mikael	Former Officer	May 05 '25	Proposed Sale	23.87	55,000	1,312,736		May 05 04:45 PM
DAMICO JENNIFER B.	SVP & Controller	Mar 04 '25	Sale	25.93	2,500	64,825	11,850	Mar 06 01:57 PM
DAMICO JENNIFER B.	SVP & Controller	Feb 27 '25	Option Exercise	31.31	22,416	701,845	31,063	Mar 03 05:39 PM
SUSMAN SALLY	Executive Vice President	Feb 27 '25	Option Exercise	31.31	85,182	2,667,048	250,866	Mar 03 05:38 PM
SAHNI PAYAL	Executive Vice President	Feb 27 '25	Option Exercise	31.31	19,054	596,581	44,242	Mar 03 05:38 PM
McDermott Michael	Executive Vice President	Feb 27 '25	Option Exercise	31.31	48,419	1,515,999	122,413	Mar 03 05:37 PM
LANKLER DOUGLAS M	Executive Vice President	Feb 27 '25	Option Exercise	31.31	156,914	4,912,977	309,790	Mar 03 05:37 PM
Fonseca Lidia	Executive Vice President	Feb 27 '25	Option Exercise	31.31	72,629	2,274,014	111,534	Mar 03 05:36 PM
BOURLA ALBERT	Chairman & CEO	Feb 27 '25	Option Exercise	31.31	582,823	18,248,188	931,744	Mar 03 05:36 PM
McDermott Michael	Executive Vice President	Feb 22 '25	Option Exercise	30.17	11,125	335,641	87,636	Feb 25 07:38 PM
DAMICO JENNIFER B.	SVP & Controller	Feb 22 '25	Option Exercise	30.17	8,741	263,716	17,602	Feb 25 07:38 PM
BOURLA ALBERT	Chairman & CEO	Feb 22 '25	Option Exercise	30.17	238,399	7,192,498	570,436	Feb 25 07:06 PM
LANKLER DOUGLAS M	Executive Vice President	Feb 22 '25	Option Exercise	30.17	85,824	2,589,310	232,775	Feb 25 07:05 PM
SAHNI PAYAL	Executive Vice President	Feb 22 '25	Option Exercise	30.17	12,714	383,581	37,099	Feb 25 07:04 PM
SUSMAN SALLY	Executive Vice President	Feb 22 '25	Option Exercise	30.17	63,573	1,917,997	225,184	Feb 25 07:02 PM
BOSHOFF CHRISTOFFEL	President, R&D	Feb 22 '25	Option Exercise	30.17	8,741	263,716	159,085	Feb 25 06:58 PM
BLAYLOCK RONALD E	Director	Feb 13 '25	Buy	25.65	19,457	499,072	27,707	Feb 14 05:16 PM

Black Swan Sale

50% Off Elite

ILMN

Illumina Inc

TEM

Tempus AI Inc

PFE

Pfizer Inc

Upgrade your FINVIZ experience